Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $241.0 million.

  • Fulcrum Therapeutics' Cash & Equivalents rose 176.26% to $200.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.6 million, marking a year-over-year increase of 176.26%. This contributed to the annual value of $241.0 million for FY2024, which is 2.03% up from last year.
  • Per Fulcrum Therapeutics' latest filing, its Cash & Equivalents stood at $241.0 million for FY2024, which was up 2.03% from $236.2 million recorded in FY2023.
  • Over the past 5 years, Fulcrum Therapeutics' Cash & Equivalents peaked at $241.0 million during FY2024, and registered a low of $35.1 million during FY2022.
  • For the 3-year period, Fulcrum Therapeutics' Cash & Equivalents averaged around $170.8 million, with its median value being $236.2 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 41.01% in 2020, then soared by 573.03% in 2023.
  • Over the past 5 years, Fulcrum Therapeutics' Cash & Equivalents (Yearly) stood at $57.1 million in 2020, then slumped by 37.93% to $35.4 million in 2021, then fell by 0.89% to $35.1 million in 2022, then spiked by 573.03% to $236.2 million in 2023, then climbed by 2.03% to $241.0 million in 2024.